Reference list
  1. Lee, K. W., Okin, P. M., Kligfield, P., Stein, K. M., & Lerman, B. B. (1997). Precordial QT dispersion and inducible ventricular tachycardia. American heart journal, 134 (6), 1005-1013.
  2. Priori, S. G., Napolitano, C., Diehl, L., & Schwartz, P. J. (1994). Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation, 89 (4), 1681-1689.
  3. Nousiainen, T., Jantunen, E., Vanninen, E., Remes, J., Puustinen, J., Rantala, A., . . . Hartikainen, J. (1998). Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients.European journal of hematology, 61 (5), 347-353.
  4. Roden, D. M. (2008). Long-QT syndrome. New England Journal of Medicine, 358 (2), 169-176.
  5. Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., . . Quinones, M. A. (2006). ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). Journal of the American College of Cardiology, 48 (5), 1064-1108.
  6. Day, C. P., McComb, J. M., & Campbell, R. W. (1990). QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.Heart, 63 (6), 342-344.
  7. Bovelli, D., Plataniotis, G., Roila, F., & Group, E. G. W. (2010). Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of oncology, 21 (suppl_5), v277-v282.
  8. Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., . . . Lyon, A. R. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European heart journal, 37 (36), 2768-2801.
  9. Strevel, E. L., Ing, D. J., & Siu, L. L. (2007). Molecularly targeted oncology therapeutics and prolongation of the QT interval.Journal of Clinical Oncology, 25 (22), 3362-3371.
  10. Shuykova, K. V., Storozhakov, G. I., Gendlin, G. E., & al., e. (2010). The case of acute anthracyclines cardiotoxicity. In. Abstracts of XXXIII World Congress of the ISH, Jerusalem, Israel.